文献速递新生儿儿童呼吸

喉罩给予肺表面活性物质减少早产儿插管:随机对照试验

Laryngeal Mask Airway for Surfactant Administration in Neonates: A Randomized, Controlled Trial.
PubMed 文献 · J Pediatr · 2017-11-22

这项前瞻性多中心随机对照试验纳入103例胎龄280/7–356/7周、体重≥1250 g、出生≤36小时、CPAP下FiO2 0.30–0.40的中度呼吸窘迫综合征早产儿,比较经喉罩给予肺表面活性物质与单纯CPAP。结果显示喉罩组7天内插管机械通气率显著低于对照组(38% vs 64%),无与喉罩置入或给药相关的严重不良事件。

要点

  • 经喉罩给予肺表面活性物质可降低中度RDS早产儿7天内插管机械通气率。
  • 插管率38% vs 64%,OR 0.30(95%CI 0.13,0.70),P=.006,NNT=4。
  • 未报告与喉罩置入或肺表面活性物质给药相关的严重不良事件。

核心结论

  • 在CPAP下FiO2 0.30–0.40的中度呼吸窘迫综合征早产儿中,经喉罩给予肺表面活性物质可降低7天内插管和机械通气率。

研究设计与样本

  • 前瞻性、多中心、随机对照试验纳入103例胎龄280/7–356/7周、体重≥1250 g、出生≤36小时、CPAP下FiO2 0.30–0.40的早产儿。
  • 婴儿随机分为经喉罩给予肺表面活性物质后重回CPAP组(LMA组,n=50)与继续CPAP不给肺表面活性物质组(对照组,n=53)。
  • 主要结局为出生后7天内治疗失败需插管和机械通气。

主要发现

  • LMA组插管和机械通气率为38%,对照组为64%,OR 0.30(95%CI 0.13,0.70),P=.006,需治疗人数为4。
  • 未报告与喉罩置入或肺表面活性物质给药相关的严重不良事件。

关键数值与推荐

  • 纳入标准:胎龄280/7–356/7周、体重≥1250 g、出生≤36小时、CPAP下需FiO2 0.30–0.40。
  • 主要结局:出生后7天内因治疗失败需插管和机械通气。
  • LMA组插管率38% vs 对照组64%,OR 0.30(95%CI 0.13,0.70),P=.006,NNT=4。

临床怎么用

  • 对符合入选条件的中度呼吸窘迫综合征早产儿,可考虑经喉罩给予肺表面活性物质作为减少插管机械通气的干预。
  • 该干预可能对高资源和低资源环境下的临床照护均有显著影响。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: To determine if preterm infants with moderate respiratory distress syndrome on continuous positive airway pressure (CPAP) who received surfactant via a laryngeal mask airway (LMA) would have a decreased rate of intubation and mechanical ventilation compared with those on CPAP who did not receive surfactant. STUDY DESIGN: In this prospective, multicenter, randomized controlled trial, 103 premature infants 280/7-356/7 weeks gestation, ≥1250 g and ≤36 hours old on CPAP requiring fraction of inspired oxygen 0.30-0.40 were assigned to receive surfactant administered through an LMA then placed back on CPAP (LMA group) or maintained on CPAP with no surfactant administered (control group). The primary outcome was treatment failure necessitating intubation and mechanical ventilation in the first 7 days of life. RESULTS: Surfactant administration through an LMA (n = 50) significantly decreased the rate of intubation and mechanical ventilation compared with controls (n = 53): 38% vs 64%, respectively, OR 0.30 (95% CI 0.13, 0.70), P = .006, number needed to treat: 4). There were no serious adverse events associated with placement of the LMA or surfactant administration. CONCLUSIONS: In premature neonates with moderate respiratory distress syndrome, surfactant administered through an LMA decreased the rate of intubation and mechanical ventilation. This intervention may have significant impact on clinical care in both high and low resource settings. TRIAL REGISTRATION: ClinicalTrials.gov: NCT01116921.

来源:J Pediatr,查看原文。版权归原作者所有。

引用

  1. Roberts KD, Brown R, Lampland AL, et al. Laryngeal Mask Airway for Surfactant Administration in Neonates: A Randomized, Controlled Trial. J Pediatr. 2017. PMID: 29174079. doi:10.1016/j.jpeds.2017.09.068

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。